LEXXW - Lexaria is Receiving Four New Patents
(TheNewswire)
Kelowna, B C - TheNewswire - April 20, 2023 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the“ Company ” or “ Lexaria ”), a global innovator in drugdelivery platforms announces that it hasreceived notifications of four new patents either awarded orallowed.
In Japan, Lexaria has received a new patent under itsPatent Family #3: StableReady-to-Drink Beverage Compositions Comprising Lipophilic ActiveAgents . This is Lexaria’s 5 th awarded patentin Japan, providing strength to our growing Japanese patent portfolio.Lexaria has existing patents under this Patent Family in Australia,India, Japan, and Mexico.
In Australia, Lexaria has received a new patent underits Patent Family #18: Compositions and Methods for Enhanced Delivery of AntiviralAgents . This is Lexaria’s 10 th patent inAustralia and only our second patent in this Patent Family, followinga similar patent award in 2022 in the USA.
In Canada, Lexaria has been advised that a new patentunder our Patent Family #8: Compositions Infused With Nicotine Compounds and Methods of UseThereof has been allowed. This is Lexaria’ssecond patent in this Patent Family and follows a similar patentissuance in Australia in 2022.
In the USA, Lexaria has been advised that a new patentunder our Patent Family #21: Compositions and Methods for Treating Hypertension has been allowed. Lexaria believes this patent could be ofparticular importance related to the Company’s pursuit of utilizingDehydraTECH-CBD in relation to its expected upcoming FDAInvestigational New Drug application. The outcomes of our series ofhypertension studies already completed were instrumental in achievingthis patent. This will be Lexaria’s first patent in this PatentFamily.
The global cardiovascular drugs market was worth US$146.5 billionin 2022 and expected to reach $173.5 billion in2026 and by geography, North Americais the biggest market in the world making US patent protection anecessity in the pursuit of commercial markets.
When a patent is “allowed”, it means we have beennotified by the patent office that they have determined they will soongrant the patent, often subject to some administrative tasks and/orfees. Lexaria is continuously pursuing additional patent protectionfor its innovative DehydraTECH drug delivery technology. After theawarding of these patents, Lexaria’s total patent portfolio willhave grown to 32 granted patents worldwide.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream through oral delivery. Since2016, DehydraTECH has repeatedly demonstrated the ability to increasebio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors andmore. DehydraTECH has also evidenced an ability to deliver some drugsmore effectively across the blood brain barrier. Lexaria operates alicensed in-house research laboratory and holds a robust intellectualproperty portfolio with 28 patents granted andmany patents pending worldwide. For more information, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS
This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the company relating the Company’sability to carry out research initiatives, receive regulatoryapprovals or grants or experience positive effects or results from anyresearch or study. Such forward-looking statements are estimatesreflecting the Company's best judgment based upon current informationand involve a number of risks and uncertainties, and there can be noassurance that the Company will actually achieve the plans,intentions, or expectations disclosed in these forward-lookingstatements. As such, you should not place undue reliance on theseforward-looking statements. Factors which could cause actual resultsto differ materially from those estimated by the Company include, butare not limited to, government regulation and regulatory approvals,managing and maintaining growth, the effect of adverse publicity,litigation, competition, scientific discovery, the patent applicationand approval process, potential adverse effects arising from thetesting or use of products utilizing the DehydraTECH technology, theCompany’s ability to maintain existing collaborations and realizethe benefits thereof, delays or cancellations of planned R&D thatcould occur related to pandemics or for other reasons, and otherfactors which may be identified from time to time in the Company'spublic announcements and periodic filings with the US Securities andExchange Commission on EDGAR. The Company provides links tothird-party websites only as a courtesy to readers and disclaims anyresponsibility for the thoroughness, accuracy or timeliness ofinformation at third-party websites. There is no assurance that any ofLexaria’s postulated uses, benefits, or advantages for the patentedand patent-pending technology will in fact be realized in any manneror in any part. No statement herein has been evaluated by the Food andDrug Administration (FDA). Lexaria-associated products are notintended to diagnose, treat, cure or prevent any disease. Anyforward-looking statements contained in this release speak only as ofthe date hereof, and the Company expressly disclaims any obligation toupdate any forward-looking statements or links to third-party websitescontained herein, whether as a result of any new information, futureevents, changed circumstances or otherwise, except as otherwiserequired by law.
INVESTOR CONTACT:
George Jurcic - Head of InvestorRelations
Copyright (c) 2023 TheNewswire - All rights reserved.